Business Context and Reporting Period
This Form 8-K filing by Biomerica, Inc. (BMRA) is dated November 6, 2024. The report addresses a regulatory matter concerning the continued listing of the Company's common stock on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on listing compliance status.
Material Changes and Listing Status
- Deficiency Notice: On May 7, 2024, the Company received notice from Nasdaq that its common stock closing bid price had been below $1.00 per share for 32 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Extension Granted: On November 5, 2024, Nasdaq granted the Company an additional 180 calendar days to regain compliance.
- Compliance Deadline: The new deadline to demonstrate compliance is May 5, 2025.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days prior to May 5, 2025.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the bid price and consider available options to resolve the deficiency. The filing explicitly states there is no assurance that the Company will regain compliance. If the Company fails to meet the requirement by May 5, 2025, Nasdaq will provide notice that the stock will be subject to delisting. The Company retains the right to appeal a delisting determination to a Nasdaq Hearings Panel.
Investor Verification Checklist
- Verify the current closing bid price of BMRA stock relative to the $1.00 threshold.
- Monitor the stock price trajectory to ensure it meets the 10 consecutive business day requirement before May 5, 2025.
- Review future filings for any announcements regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Confirm whether the Company has filed an appeal if a delisting notice is issued after the May 5, 2025 deadline.